Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants

Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants

Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1.

Data obtained showed substantial CD8+ T-cell responses against SARS-Cov-2 and showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43.   

In a comparative experiment, Phase 1 study data was compared to T-cell responses from volunteers subsequently vaccinated with the Moderna Inc’s (NASDAQ: MRNA) or Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccines, indicating the mRNA vaccines induced fewer T-cell responses.

“The strength of T-cell responses against both S and N proteins, which we targeted, leads us to believe that VXA-CoV2-1 offers a promising solution to variants,” said Dr. Sean Tucker, chief scientific officer at Vaxart.

Price Action: VXRT shares up 17.5% at $9.42 in the premarket session on the last check Tuesday.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Dick Kaplan 1 day ago Member's comment

This is far too preliminary to justify such a surge in stock price. The headline says it all: it “COULD” protect against variants, but that's far from guaranteed. It's only in phase 1. It has phase 2 and phase 3 to hurdle before it can even be sold.

Carl Schwartz 1 day ago Member's comment

Agreed. Time will bring it down like every other biotech in its history. Companies love to try to pump up the stock price with announcements like this.